Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03167216 · ClinicalTrials.gov registry record · Early Phase 1
Mast Cells in Male Pelvic Pain and and Lower Urinary Tract Dysfunction
A Early Phase 1 study, sponsored by Northwestern University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
NCT03167216 is a Early Phase 1 study that has completed, run by Northwestern University. The registered enrollment target is 20 participants.
The verdict
NCT03167216, a Early Phase 1 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate inhibition of mast cells and the histamine 1 receptor (H1R) for treatment of chronic prostatitis (CP) and chronic pelvic pain syndrome (CPPS).
Interventions
- DRUG Cromolyn Sodium
- DRUG Cetirizine Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-08-01 |
| Est. Completion | 2022-06-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03167216
The ClinicalTrials.gov registry entry for NCT03167216 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cromolyn Sodium is the first listed.
NCT03167216 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03167216 about?
NCT03167216 is a clinical study titled "Mast Cells in Male Pelvic Pain and and Lower Urinary Tract Dysfunction". The objective of this study is to evaluate inhibition of mast cells and the histamine 1 receptor (H1R) for treatment of chronic prostatitis (CP) and chronic pelvic pain syndrome (CPPS).
What is the current status of trial NCT03167216?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2017-08-01. Estimated completion is 2022-06-30.
What interventions are being tested in trial NCT03167216?
The interventions under investigation include: Cromolyn Sodium (DRUG), Cetirizine Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT03167216?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.